Miles Carroll
Professor of Emerging Viruses
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
Recent publications
The development of biologically contained Sudan virus as an alternative and safe tool for fundamental filovirus research.
Journal article
Verlinden J. et al, (2026), Emerg Microbes Infect, 15
Identifying molecular signatures underpinning treatment responses to novel therapeutics influencing COVID-19 outcomes.
Journal article
Ackland J. et al, (2026), J Immunol, 215
Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot Study.
Journal article
Alsaleh G. et al, (2026), Aging Cell, 25
Cephalosporins are potent SARS-CoV-2 main protease inhibitors.
Journal article
Muntean D-G. et al, (2026), Eur J Med Chem, 316
ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
Journal article
Tipton T. et al, (2026), Vaccine, 72